A 24-year-old man with fibrodysplasia ossificans progressiva: clinical challenges and management

Syed Jamil Abdal; Sabrina Yesmin; M. Abu Shahin; M. Ariful Islam; Syed Atiqul Haq; Sharmin Nahar

doi:10.18203/2320-6012.ijrms20251324

Authors

Syed Jamil Abdal Department of Rheumatology, Bangladesh Medical University (Formerly Bangabandhu Sheikh Mujib Medical University), Shahbag, Dhaka, Bangladesh
Sabrina Yesmin Department of Rheumatology, Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders (BIRDEM), Shahbag, Dhaka, Bangladesh
M. Abu Shahin Department of Rheumatology, Bangladesh Medical University (Formerly Bangabandhu Sheikh Mujib Medical University), Shahbag, Dhaka, Bangladesh
M. Ariful Islam Department of Rheumatology, Bangladesh Medical University (Formerly Bangabandhu Sheikh Mujib Medical University), Shahbag, Dhaka, Bangladesh
Syed Atiqul Haq Green Life Center for Rheumatic Care and Research, 32 Green Road, Dhaka, Bangladesh
Sharmin Nahar Department of Rheumatology, Bangabandhu Sheikh Mujib Medical University, Shahbag, Dhaka, Bangladesh

DOI:

https://doi.org/10.18203/2320-6012.ijrms20251324

Keywords:

Fibrodysplasia, Heterotopic ossification, ACVR1 gene mutation, Bone morphogenic protein

Abstract

Fibrodysplasia ossificans progressiva (FOP) is a rare, disabling genetic disorder characterized by progressive heterotopic ossification of skeletal muscles and connective tissues. It is recognized as the most disabling condition of extraskeletal bone formation. The worldwide prevalence is approximately 1 in 2,000,000, with no ethnic, racial, gender, or geographic predilection. The hallmark clinical features include congenital malformation of great toes (commonly bilateral hallux valgus) and recurrent episodes of heterotopic ossification, often triggered by trauma or occurring spontaneously. Pathogenesis involves dysregulated bone morphogenetic protein (BMP) signaling due to mutation in the ACVR1 gene. Here we report a case of 24-year-old male with classical FOP, presenting with bilateral deformities of the big toes and progressive ectopic ossification. Despite advances in understanding the molecular mechanisms of the disease, there are currently no definitive preventive treatments. Early recognition of FOP, particularly by pediatric clinicians, is critical to avoid exacerbating factors, such as invasive procedures or trauma that may accelerate disease progression. This case report highlights the importance of clinical vigilance and continued research into therapeutic options for this devastating condition.

Metrics

Metrics Loading ...

References

Kaplan FS, Le Merrer M, Glaser DL, Pignolo RJ, Goldsby RE, Kitterman JA, et al. Fibrodysplasia ossificans progressiva. Best Pract Res Clin Rheumatol. 2008;22(1):191-205. DOI: https://doi.org/10.1016/j.berh.2007.11.007

Freke J. A letter from Mr. John Freke, F. R. S. Surgeon to St. Bartholomew's Hospital to the Royal Society, relating a case of extraordinary exostoses on the back of boy. Phil Trans R Soc. 1740;41(456):369-70. DOI: https://doi.org/10.1098/rstl.1739.0066

McKusick V. Chapter 12: Other heritable and generalized disorders of connective tissue. Heritable Disorders of Connective Tissue. Fourth edition. The C.V. Mosby Company, St. Louis. 1972.

Pignolo RJ, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva: clinical and genetic aspects. Orphanet J Rare Dis. 2011;6:80.

Houssni JE, Jellal S, Dehayni F, Neftah I, Haddad SE, Allali N, et al. Fibrodysplasia ossificans progressiva associated with osteochondromatosis: A case report. Radiol Case Rep. 2024;20(1):256-60. DOI: https://doi.org/10.1016/j.radcr.2024.09.152

Pignolo RJ, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva: clinical and genetic aspects. Orphanet J Rare Dis. 2011;6:80. DOI: https://doi.org/10.1186/1750-1172-6-80

Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho TJ, Choi IH, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. 2006;38(5):525-7. DOI: https://doi.org/10.1038/ng1783

Cohen RB, Hahn GV, Tabas JA, Peeper J, Levitz CL, Sando A, et al. The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. A study of forty-four patients. J Bone Joint Surg Am. 1993;75(2):215-9. DOI: https://doi.org/10.2106/00004623-199302000-00008

Rocke DM, Zasloff M, Peeper J, Cohen RB, Kaplan FS. Age and joint-specific risk of initial heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. Clin Orthop Rel Res. 1994;301:243-8. DOI: https://doi.org/10.1097/00003086-199404000-00038

Kitterman JA, Kantanie S, Rocke DM, Kaplan FS. Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva. Pediatrics. 2005;116:e654-61. DOI: https://doi.org/10.1542/peds.2005-0469

Zaghloul KA, Heuer GG, Guttenberg MD, Shore EM, Kaplan FS, Storm PB. Lumbar puncture and surgical intervention in a child with undiagnosed fibrodysplasia ossificans progressiva. J Neurosurg Pediatr. 2008;1:91-4. DOI: https://doi.org/10.3171/PED-08/01/091

Pignolo RJ, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons. Pediatr Endocrinol Rev. 2013;10(02):437-48.

Shaikh U, Khan A, Kumari P, Ishfaq A, Ekhator C, Yousuf P, et al. Novel Therapeutic Targets for Fibrodysplasia Ossificans Progressiva: Emerging Strategies and Future Directions. Cureus. 2023;15(7):e42614. DOI: https://doi.org/10.7759/cureus.42614